B*44 restricted peptides for use in immunotherapy against cancers and related methods
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 283,
wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell,
wherein said cancer is selected from, breast cancer, cholangiocellular carcinoma, chronic lymphocytic leukemia, colorectal cancer, gallbladder cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, melanoma, non-small cell lung cancer, ovarian cancer, esophageal cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, urinary bladder carcinoma, and uterine and endometrial cancer.
2. The method of claim 1 , wherein the T cells are autologous to the patient.
3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.
4. The method of claim 1 , wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.
5. The method of claim 1 , further comprising administering to said patient an adjuvant selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides, poly-(I:C), RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.
6. The method of claim 5 , wherein the adjuvant comprises IL-21.
7. The method of claim 1 , wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide.
8. The method of claim 1 , wherein the antigen presenting cell is a dendritic cell or a macrophage.
9. The method of claim 1 , wherein the contacting is in the presence of an anti-CD28 antibody and IL-12.
10. The method of claim 1 , wherein the cancer is breast cancer.
11. The method of claim 1 , wherein the cancer is colorectal cancer.
12. The method of claim 1 , wherein the cancer is prostate cancer.
13. The method of claim 1 , wherein the cancer is non-small cell lung cancer.
14. The method of claim 1 , wherein the cancer is hepatocellular carcinoma.
15. The method of claim 1 , wherein the cancer is melanoma.
16. A method of treating a patient who has, breast cancer, cholangiocellular carcinoma, chronic lymphocytic leukemia, colorectal cancer, gallbladder cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, melanoma, non-small cell lung cancer, ovarian cancer, esophageal cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, urinary bladder carcinoma, and uterine and endometrial cancer, comprising administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, wherein said peptide consists of the amino acid sequence of SEQ ID NO: 283, thereby inducing a T-cell response to the, breast cancer, cholangiocellular carcinoma, chronic lymphocytic leukemia, colorectal cancer, gallbladder cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, melanoma, non-small cell lung cancer, ovarian cancer, esophageal cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, urinary bladder carcinoma, and uterine and endometrial cancer.
17. The method of claim 16 , wherein the cancer is breast cancer.
18. The method of claim 16 , wherein the cancer is colorectal cancer.
19. The method of claim 16 , wherein the cancer is prostate cancer.
20. The method of claim 16 , wherein the cancer is non-small cell lung cancer.